It includes multiple trials, each examining different aspects of the 2.4mg dosing protocol
Research published in the journal Diabetes, Obesity and Metabolism documented significant decreases in serum B12 levels in patients taking once-weekly semaglutide, alongside drops in zinc and albumin
Depending on the dose and indication, up to 70% of patients may experience some GI effects, with higher rates typically seen at weight management doses (2.4 mg) and during dose escalation
Liraglutide inhibits endothelial-to-mesenchymal transition and attenuates neointima formation after endovascular injury in streptozotocin-induced diabetic mice
(n.d.) Pi-Sunyer, Xavier, et al (2015) A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management Campbell, Sydney et al
The most successful and sustainable weight loss happens when medication is combined with healthy lifestyle habits